Biocompatibility of heparin-coated cardiopulmonary bypass circuits in coronary patients with left ventricular dysfunction is superior to PMEA-coated circuits

Journal of Cardiac Surgery

Volumn 21, Issue 6, 2006, Pages 572-577

  Kutay, Veysel ^a   Noyan, Tevfik ^a   Ozcan, Sedat ^a   Melek, Yasin ^a   Ekim, Hasan ^a   Yakut, Cevat ^a  

^a YUZUNCU YIL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALBUMIN; C REACTIVE PROTEIN; CATALASE; FIBRINOGEN; HEPARIN; INTERLEUKIN 8; MALONALDEHYDE; MYELOPEROXIDASE; PLASMA PROTEIN; TROPONIN I;

ADULT; AGED; ARTICLE; BIOCOMPATIBILITY; CARDIOPULMONARY BYPASS; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DRUG EFFICACY; FEMALE; FIBRINOGEN BLOOD LEVEL; HEART DISEASE; HUMAN; INFLAMMATION; LEUKOCYTE COUNT; MALE; NEUTROPHIL COUNT; THROMBOCYTE COUNT; TREATMENT OUTCOME;

ACRYLATES; AGED; ALBUMINS; ANTICOAGULANTS; BLOOD CELL COUNT; CARDIOPULMONARY BYPASS; COATED MATERIALS, BIOCOMPATIBLE; CORONARY ARTERY BYPASS; FEMALE; FIBRINOGEN; HEPARIN; HUMANS; INTERLEUKIN-8; MALE; MIDDLE AGED; PEROXIDASE; POLYMERS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33750432178     PISSN: 08860440     EISSN: 15408191     Source Type: Journal    
DOI: 10.1111/j.1540-8191.2006.00298.x     Document Type: Article

References (23)

1. Edmunds LH: Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 1998;66:S12-S16.
2. Levy JH, Tanaka KA: Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 2003;75:S715-S720.
3. Paparella D, Yau TM, Young E: Cardiopulmonary bypass induced inflammation: Pathophysiology and treatment. An update. Eur J Cardiothorac Surg 2002;21:232-244.
4. Wendel HP, Ziemer G: Coating-techniques to improve the hemocompatibility of artificial devices used for extracorporeal circulation: Eur J Cardiothorac Surg 1999;16:342-350.
5. Tanaka M, Motomura T, Kawada M, et al: Blood compatible aspects of poly 2-methoxyethylacrylate (PMEA)-relationship between protein adsorption and platelet adhesion on PMEA surface. Biomaterials 2000;21:1471-1481.
6. Suhara H, Sawa Y, Nishimura M, et al: Efficacy of a new coating material, PMEA, for cardiopulmonary bypass circuits in a porcine model. Ann Thorac Surg 2001;71:1603-1608.
7. Gunaydin S, Farsak B, Kocakulak M, et al: Clinical performance and biocompatibility of Poly(2-Methoxyethylacrylate)-coated extra-corporeal circuits. Ann Thorac Surg 2002;74:819-824.
8. Ninomiya M, Miyaji K, Takamoto S: Influence of PMEA-coated bypass circuits on perioperative inflammatory response. Ann Thorac Surg 2003;75:913-918.
9. Ikuta T, Fujii H, Shibata T, et al: A new poly-2-methoxyethylacrylate- coated cardiopulmonary bypass circuit possesses superior platelet preservation and inflammatory suppression efficacy. Ann Thorac Surg 2004;77:1678-1683.
10. Gu YJ, van Oeveren W, Akkerman C, et al: Heparin-coated circuits reduce the inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 1993;55:917-922.
11. Moen O, Hogasen K, Fosse E, et al: Attenuation of changes in leukocyte surface markers and complement activation with heparin-coated cardiopulmonary bypass. Ann Thorac Surg 1997;63:105-111.
12. Belboul A, Löfgren C, Storm C, et al: Heparin-coated circuits reduce occult myocardial damage during CPB: A randomized, single blind clinical trial. Eur J Cardiothorac Surg 2000;17:580-586.
13. Ranucci M, Mazzucco A, Pessotto R, et al: Heparin-coated circuits for high-risk patients: A multicenter, prospective, randomized trial. Ann Thorac Surg 1999;67:994-1000.
14. Øvrum E, Tangen G, Tollofsrud S, et al: Heparin-coated circuits and reduced systemic anticoagulation applied to 2500 consecutive first-time coronary artery bypass grafting procedures. Ann Thorac Surg 2003;76:1144-1148.
15. Gott VL, Whiffen JD, Dutton RC: Heparin bonding on colloidal graphite surfaces. Science 1963;142:1297-1298.
16. Øvrum E, Holen EA, Tangen G, et al: Completely heparinized cardiopulmonary bypass and reduced systemic heparin: Clinical and hemostatic effects. Ann Thorac Surg 1995;60:365-371.
17. Ranucci M, Cazzaniga A, Soro G, et al: The antithrombin III-saving effect of reduced systemic heparinization and heparin-coated circuits. J Cardiothorac Vasc Anesth 2002;16:316-320.
18. Kumano H, Suehiro S, Hattori K, et al: Coagulofibrinolysis during heparin-coated cardiopulmonary bypass with reduced heparinization. Ann Thorac Surg 1999;68:1252-1256.
19. Redmond JM, Gillinov AM, Stuart RS, et al: Heparin-coated bypass circuits reduce pulmonary injury. Ann Thorac Surg 1993;56:474-479.
20. Shandelya SM, Kuppusamy P, Weisfeldt ML, et al: Evaluation of polymorphonuclear leukocytes on contractile function in myocardial reperfusion injury: Evidence for plasma-mediated leukocte activation. Circulation 1993;87:536-546.
21. Wan S, Yim APC: Cytokines in myocardial injury: Impact on cardiac surgical approach. Eur J Cardiothorac Surg 1999;16:S107-S111.
22. Boyle EM, Kovacich JC, Hebert CA, et al: Inhibition of IL-8 blocks myocardial ischemia-reperfusion injury. J Thorac Cardiovasc Surg 1998;116:114-121.
23. Nathan N, Denizot Y, Cornu E, et al: Cytokine and lipid mediator blood concentrations after coronary artery surgery. Anesth Analg 1997;85:1240-1246.